0
Obstructive Lung Diseases: Airways 1 |

Frequency of Exacerbations in COPD: The Efficacy of Carbocysteine Lysine Salt With or Without Inhaled Steroids

Federico Saibene, MD; Gregorino Paone, MD; Luigi Lanata, MD; Renato Delli Colli, MD; Giovanni Puglisi, MD
Author and Funding Information

Dompé Farmaceutici SpA, Milan, Italy


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;150(4_S):826A. doi:10.1016/j.chest.2016.08.926
Text Size: A A A
Published online

Extract

SESSION TITLE: Airways 1

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the world and it is characterized by airflow limitation. Pathophysiologically COPD involves many components including mucus hypersecretion, oxidative stress and inflammation, contributing to corticosteroid resistance. Carbocysteine lysine salt (CLS) is a mucoactive drug with mucoregulatory, anti-inflammatory, antioxidative effects and could also restore steroid sensitivity, offering promise for treatment. Assessment of COPD is also based on risk of exacerbation. The results of PEACE study showed that long-term use of carbocysteine lead to a 25% reduction of exacerbations in GOLD II-IV, with significant benefit in patients with > 1 exacerbation. However, only 17% of PEACE study patients received background therapy including inhaled steroids (IS). The aim of this observational prospective real life clinical trial was to evaluate the correlation between frequency of exacerbations in patients that experienced more than 2 episodes during the study and treatment adopted, included CLS with or without IS.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543